To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Additional recommended knowledge
Occurrence in nature
Harmaline is a central nervous system stimulant and a "reversible inhibitor of MAO-A (RIMA)." It being selectively an MAO-A inhibitor means that it only binds to MAO-A and it leaves MAO-B free to metabolize tyrosine-containing foods that can be dangerous with MAO-B inhibitors. The reversibility means that, instead of binding permanently to MAO-A for weeks until the body replaces the MAO-A enzyme molecules, harmaline binds to the MAO-A enzyme for only up to 24 hours until it "reverses" its inhibition by separating from MAO-A. This means that the risk of a hypertensive crisis, a dangerous high blood pressure crisis from eating tyrosine-rich foods such as cheese, is potentially lower with harmaline than with non-reversible MAOI's, especially after 24 hours following ingestion.
Depending upon the dosage, harmaline induces temporary oneirophrenia and ataxia. Harmaline, on the higher end of its safe dosage range, has hallucinogenic properties, but it differentiates itself significantly from the "classical" hallucinogens in its pharmacology. Since harmaline is a reversible monoamine oxidase inhibitor, it could increase the effect of some drugs problematically. Harmaline causes no known physical or psychological dependence.
United States Patent Number 5591738 describes a method for treating various chemical dependencies via the administration of harmaline and or other beta-carbolines.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Harmaline". A list of authors is available in Wikipedia.|